NCT Number: NCT05011383
Phase: Phase 2
Trial Summary: This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): VA Office of Research and Development
Acronym: VA-BAT
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives